Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 42,642 Shares of Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 42,642 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $65.43, for a total value of $2,790,066.06. Following the completion of the sale, the director directly owned 1,139,862 shares of the company’s stock, valued at approximately $74,581,170.66. This trade represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total value of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total value of $1,985,108.84.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The shares were sold at an average price of $65.23, for a total value of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The shares were sold at an average price of $60.08, for a total value of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Stock Performance

Shares of Establishment Labs stock opened at $65.47 on Tuesday. The firm’s fifty day simple moving average is $66.15 and its 200-day simple moving average is $65.53. Establishment Labs Holdings Inc. has a 12 month low of $28.89 and a 12 month high of $83.31. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -37.63 and a beta of 1.08. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.13. The company had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. Establishment Labs’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the firm posted ($1.19) EPS. As a group, equities analysts forecast that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after acquiring an additional 9,557 shares during the period. Geode Capital Management LLC grew its stake in shares of Establishment Labs by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after purchasing an additional 299 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Establishment Labs during the 2nd quarter worth $651,000. Nebula Research & Development LLC increased its holdings in shares of Establishment Labs by 27.9% in the 2nd quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after purchasing an additional 3,538 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in shares of Establishment Labs by 13.3% in the 2nd quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock valued at $2,068,000 after purchasing an additional 5,668 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ESTA shares. Stephens upped their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group boosted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Citigroup reduced their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Finally, Needham & Company LLC lifted their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.